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Abstract 
AIM: To compare the ability of four strains of Streptococcus uberis at two doses to induce clinical 
mastitis in lactating dairy cows after intramammary inoculation in order to evaluate their usefulness 
for future experimental infection models.  
MATERIALS AND METHODS: Four field strains of Streptococcus uberis (26LB, S418, and S523 
and SR115) were obtained from cows with clinical mastitis in the Wairarapa and Waikato regions 
of New Zealand. Twenty-four crossbred lactating cows, with no history of mastitis and absence of 
major pathogens following culture of milk samples, were randomly allocated to four groups (one 
per strain) of six cows. Each cow was infused (Day 0) in one quarter with approximately 104 cfu 
and in the contralateral quarter with approximately 106 cfu of the same strain. The other two 
quarters remained unchallenged. All four quarters were then inspected for signs of clinical mastitis, 
by palpation and observation of the foremilk, twice daily from Days 0–9, and composite milk 
samples were collected from Days 0–8 for analysis of somatic cell counts (SCC). Quarters were 
treated with penicillin when clinical mastitis was observed. Duplicate milk samples were collected 
and cultured on presentation of each clinical case and on Day 4 from challenged quarters with no 














































RESULTS: Clinical mastitis was diagnosed in 26/48 (54%) challenged quarters. Challenge with 
strain S418 resulted in more cases of mastitis (12/12 quarters) than strains SR115 (7/12), 26LB 
(6/12) or S523 (1/12), and the mean interval from challenge to first diagnosis of mastitis was shorter 
for S418 than the other strains (p<0.001). The proportion of quarters from which S. uberis could be 
isolated after challenge was less for strain 26LB (1/6) than SR115 (6/7) (p<0.05), and SCC 
following challenge was lower for strain S523 than the other strains (p<0.05).  
CONCLUSIONS: There were significant differences between the strains in the proportion of 
quarters developing clinical mastitis, the interval to mastitis onset, SCC following challenge and the 
proportion of clinical cases from which S. uberis could be isolated. These results illustrate the 
difference in the ability of S. uberis strains to cause mastitis and the severity of the infections 
caused.  
CLINICAL RELEVANCE: Experimental challenge models can be used to compare infectivity and 
pathogenicity of different strains of mastitis-causing bacteria, the efficacy of pharmaceutical 
products and host-responses in a cost-effective manner.  
KEY WORDS: Mastitis, Streptococcus uberis, challenge model, bovine, bacterial strains 
 
PBS Phosphate buffered saline 
SCC Somatic cell count,  
SCS Somatic cell score 
 
Introduction 
Streptococcus uberis has been reported as the predominant environmental mastitis-causing 
organism in New Zealand (Lopez-Benavides et al. 2007; McDougall et al. 2007; Petrovski et al. 
2009), and overseas (Jayarao et al. 1999; Zadoks et al. 2005). S. uberis strains differ genetically and 
consequently their virulence factors are expected to vary. For instance, the presence or absence of a 
genetically coded capsule, plasmin activator or S. uberis adherence molecule was shown to 
determine the ability of strains to colonise the mammary gland (Hill 1988a; Leigh and Lincoln 
1997; Almeida et al. 2006).  
In vivo hypothesis-testing research on bovine mastitis is generally based on comparisons between 














































infected animals can be costly and require the monitoring and use of a large number of animals to 
identify enough cases to produce adequate statistical power. This is due to the variability which 
exists between farms, infectious doses, bacterial strains and environments. Longitudinal studies 
based on the natural incidence of mastitis can require years to recruit a sufficient number of cases 
(Deluyker et al. 1999; Zadoks et al. 2001).  
Experimental infection or challenge studies require less time to acquire cases and are therefore 
quicker to conduct than field studies and should require fewer animals (Pedersen et al. 2003; 
Rambeaud et al. 2003). They also have advantages from an animal welfare perspective, as closer 
veterinary monitoring can be provided, and treatment of clinical infections can thus start earlier than 
in field studies. Many challenge models have been developed using different strains of S. uberis 
(Oliver et al. 2003; Petrovski et al. 2011), Staphylococcus aureus (Boddie and Nickerson 1996), 
Escherichia coli (Heyneman et al. 1990; Kutila et al. 2004), and other major mastitis pathogens. 
Different aspects of infection have been evaluated including the incidence of clinical mastitis after 
challenge, the incubation time to detection of clinical mastitis, the dose required to induce infection 
and the immune response (Moyes et al. 2009, 2010; Simojoki et al. 2009). S. uberis challenge 
models comparing the effects of different doses of the same strain introduced in quarters of 
different cows have also been described (McDougall et al. 2004), as well as those assessing 
between-strain variability (Hill 1988b; Pryor et al. 2009; Tassi et al. 2013; Khazandi et al. 2015).  
The aim of the present study was to develop a S. uberis intramammary infection model suitable for 
future studies. For this, four strains isolated from natural cases of mastitis in New Zealand were 
compared for their ability to cause clinical mastitis in lactating dairy cows at two different doses. 
The outcomes assessed were the proportion of quarters diagnosed with clinical mastitis following 
challenge, the interval to the onset of clinical signs and the effects of infection on somatic cell 
counts (SCC).  
Materials and methods 
Animal selection, allocation to treatments and husbandry 
The study was performed at the Massey University Nº1 Dairy farm (Palmerston North, New 
Zealand) and was approved by the AgResearch Grasslands Animal Ethics Committee (authorisation 
No 12463). The farm had a herd of approximately 170 crossbreed autumn-calving cows. All cows 
with the following parameters were eligible for enrolment in the study: four functional quarters, no 
history of mastitis in the current lactation, no antimicrobial treatments received in the 14 days prior 
to the commencement of the study and a composite milk SCC <250,000 cells/mL at a herd test 














































the mean days in milk was 174 (SE 49). Thirty-five cows met the pre-selection criteria and quarter 
milk samples were collected from these cows for bacteriological analysis. Eleven cows were 
eliminated due to contaminated samples or infection with major pathogens (S. aureus), leaving 24 
cows for enrolment. Cows with minor pathogens present (e.g. coagulase-negative staphylococci or 
Corynebacterium spp.) were included.  
Cows were allocated to one of four groups (one per strain) of six cows, using blocked 
randomisation based on milk yield at the pre-screen test. This was done by ranking the 24 cows 
according to descending milk yield and placing them into six blocks. Block 1 consisted of cows 
with the highest yields (11.5–14 L/day); Block 2 cows with milk yields between 10–11.5 L/day, 
cows in Block 3 had milk yields of 9.5 L/day, in Block 4 had yields of 9.0 L/day, in Block 5 had 
yields between 8.5–9.0 L/day, and in Block 6 between 7.5–8.0 L/day. One replicate from each 
block was randomly assigned to each of the four groups. Cows were also randomly allocated to be 
challenged in either the front right/rear left or front left/rear right contralateral quarters with either 
high or low concentrations of the challenge suspension. Another level of blocking ensured an even 
distribution of doses among front and rear quarters, so that for each strain, three cows were 
inoculated with the high dose in the front quarters. 
The challenged cows were managed as a single group, were milked twice daily and were fed by 
grazing predominantly perennial rye grass (Lolium perenne)/white clover (Trifolium repens) 
pasture. Water was available ad libitum. 
Selection of strains and preparation of the challenge suspension 
The four S. uberis strains used for the challenge originated from cows with clinical mastitis from 
the Wairarapa and Waikato regions of New Zealand. Initially, seven strains were taken at random 
from a collection maintained in glycerol at −80oC at the Institute of Veterinary, Animal and 
Biomedical Sciences microbiology laboratory (Massey University, Palmerston North, NZ). The 
strains were re-identified phenotypically as S. uberis according to the following criteria: positive 
Gram stain, negative catalase reaction, positive aesculin and inulin reactions and negative growth in 
buffered azide glucose glycerol broth. The results of a standard in vitro disc diffusion antimicrobial 
susceptibility test (Wikler et al. 2006) indicated all these isolates were susceptible to penicillin and 
the three strains showing the widest inhibition zone diameters were selected for the study (strains 
26LB, S418, and S523). This selection criterion was established to safeguard animal welfare and to 
increase the likelihood of cure after antimicrobial treatment of the induced infections. The fourth 














































Dr S McDougall (Cognosco, Anexa FVC, Morrinsville, New Zealand). Antimicrobial susceptibility 
testing indicated this strain was also susceptible to penicillin.  
Preparation of the challenge suspension of S. uberis strains was carried out as follows. Four days 
before the challenge, an aliquot of each frozen strain was streaked onto a Columbia agar plate 
supplemented with 5% defibrinated sheep blood (Fort Richard, Auckland, NZ). The plate was 
incubated at 37ºC for 48 hours in 5–10% CO2-enriched environment. The plates were observed for 
purity, and a number of colonies were suspended in 10 mL phosphate buffered saline (PBS), pH 
7.3. Bacterial suspensions were mixed and 10 sheep blood agar plates were flooded with 100 µL of 
suspension and incubated for 48 hours as above. On the day of the challenge (Day 0), bacteria were 
harvested using sterile cotton swabs and re-suspended in PBS to a visual turbidity corresponding to 
the 0.5 McFarland standard (Remel, Lenexa, KS, USA). Such a procedure was previously shown to 
generate bacterial suspensions containing approximately 107 cfu/mL (Petrovski et al. 2011). 
Following the turbidity adjustment, these suspensions were serially diluted in PBS to make 1:10 and 
1:100 dilutions. These suspensions were expected to yield bacterial counts of approximately 106 
cfu/mL (high dose) and 104 cfu/mL (low dose). The suspensions were prepared at volumes that 
were sufficient to challenge the quarters and for retrospective bacterial counting and purity testing. 
Four mL of the prepared suspensions were transferred into series of syringes for intramammary 
administration.  
Retrospective purity testing and bacterial counting was performed on the same day using aliquots of 
the PBS that was used to suspend the bacterial colonies and syringes containing microbial 
suspensions. The serial dilution viable count method conducted in triplicate was used for bacterial 
counting. Briefly, 1 mL of the contents of each one of three syringes containing the final microbial 
suspension (high and low) was serially diluted ten-fold in PBS and 100 µL-aliquots of 1:100, 
1:1,000 and 1:10,000 dilutions were spread onto blood agar plates and incubated as above. The 
arithmetic means of the number of colonies that grew on the three plates inoculated with these 
dilutions showing 30–300 bacterial colonies were used to estimate the number of cfu/mL of the 
inoculum in each challenge suspension, for each of the four strains used for the challenge. 
Challenge procedure 
Immediately after the morning milking, each cow was experimentally challenged once in two 
contralateral quarters as described above. Before inoculation, teat-ends were thoroughly cleaned 
using cotton swabs moistened with 70% ethanol. The entire contents of the syringe (4 mL) was 
inoculated into a quarter after full insertion of the syringe nozzle through the teat canal. The two 















































Clinical examinations were conducted twice daily following the challenge, for 10 consecutive days 
(Days 0–9) during each milking. Prior to milking, the foremilk of each quarter was examined for 
presence of milk clots or colour changes. Following milking, individual quarters were inspected and 
palpated for clinical signs of mastitis: heat, swelling, redness and/or pain. A clinical score (0–5) was 
determined for each quarter based on the signs observed, as previously described (Petrovski et al. 
2011). Quarters were considered to have clinical mastitis if the clinical score was ≥3, when 
evidence of irritation and/or pain of a moderate intensity or moderate redness were observed, 
swelling and/or heat of the quarter was detected and/or the secretion contained small clots or flecks. 
Scores 0–1 indicated absence of clinical mastitis. 
Quarters diagnosed with clinical mastitis were treated immediately after the milking at which the 
diagnosis was made with a penicillin-based intramammary product (Lactapen G, 26.7% w/v 
penicillin procaine, Bomac Laboratories, Ltd., Auckland, NZ) three or six times as necessary for 
recovery. A systemic penicillin-based antibiotic (Penethaject, 33% w/v penthemate hydriodide, 
Bomac Laboratories Ltd.) was used in addition to the intramammary treatment for cows which had 
quarters with clinical scores ≥4.  
Collection of milk samples 
Composite milk samples from the four quarters were collected using in-line milk samplers each 
morning from Days 0–8. These samples were used for SCC determination at a private laboratory 
(MilkTestNZ, Hamilton, New Zealand). Logistics prevented the collection of quarter milk samples 
for SCC analysis. Duplicate milk samples were collected aseptically from each quarter diagnosed 
with clinical mastitis and cultured. The second sample was cultured only if the first sample was 
considered contaminated. In order to estimate the total number of intramammary infections and 
identify non-clinical mastitis, milk samples were also collected from all the challenged quarters not 
affected with clinical mastitis on the morning of Day 4.  
Culturing of milk samples 
The culture procedures and pathogen identification followed established guidelines (Hogan et al. 
1999). Briefly, 10 µL of aseptically collected single-quarter milk from each cow was deposited as a 
drop and spread onto one quarter of a Columbia agar plate supplemented with 5% defibrinated 
sheep blood (Fort Richard). Plates were incubated at 37°C in an aerobic environment and bacterial 
growth was observed after 24 and 48 hours incubation. A sample was considered contaminated if 














































Statistical analysis  
The cumulative proportions of quarters diagnosed with clinical mastitis were calculated for each 
strain, and the relative risk for developing mastitis, with 95% CI, was calculated between strains 
using Episheet 2004 (http://www.epinet.se/Epidemiologicaltools.htm; Rothman 2002). The mean 
interval to first diagnosis of clinical mastitis for the strains (expressed as days after challenge) was 
compared using Kaplan-Meier survival analysis using XL-Stats package (XL-Stats 2012, Addinsoft 
SARL, Paris, France). The proportion of quarters with clinical mastitis from which S. uberis was 
isolated after culture was compared between strains using a two-tailed Fisher’s exact test.  
Statistical comparison of SCC was performed at the cow level, as only composite milk samples 
were collected daily. Individual cow SCC were not normally distributed and were therefore 
transformed into somatic cell scores (SCS), calculated as: 
SCS=log2 (SCC/1000) 
The effect of strain on SCS after challenge was analysed using a repeated measures analysis of 
variance using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). The model included the fixed 
effect of strain and day of sampling, the interaction of strain and dose, and a random effect of cow 
to account for within-cow correlation between measures.  
Results 
Retrospective bacterial challenge count  
The challenge suspensions of the four strains yielded pure S. uberis cultures and no bacterial growth 
was detected from the PBS alone. The results of the retrospective viable bacterial counting are 
given in Table 1. 
Diagnosis of mastitis  
Clinical mastitis was diagnosed in 26/48 (54%) challenged quarters. No unchallenged quarters 
developed clinical or subclinical mastitis, therefore no samples from unchallenged quarters were 
cultured. The proportion of quarters diagnosed with clinical mastitis for each strain and dose are 
presented in Table 1. Challenge with strain S418 resulted in more cases compared with any of the 
other strains; the RR compared with SR115 was 1.7 (95%CI=1.1–2.8); compared with 26LB was 2 
(95%CI=1.1–3.5) and with S523 was 12 (95%CI=1.8–78.4). Challenge with strains SR115 and 
26LB resulted in more cases than strain S523 (RR 7 (95%CI=0.9–52.0) and 6 (95%CI=0.8–40.3), 
respectively). The peak of clinical mastitis incidence was observed 48–72 hours after challenge. 














































the four strains (p<0.001), with the interval to diagnosis being shortest following challenge with 
strain S418 (Figure 1; Table 1).  
Streptococcus uberis was isolated from 20/26 (73%) of the clinical cases identified between Days 1 
and 4. No organisms other than S. uberis were isolated from milk samples from the clinical cases. 
Seven cases (27%) yielded no growth. Fewer clinical cases diagnosed following challenge with 
strain 26LB resulted in isolation of S. uberis, compared with strain SR115 (p<0.05; Table 1). No 
bacteria were isolated from any of the milk samples collected from the challenged quarters which 
had no clinical mastitis.  
Somatic cell count  
Mean SCS increased on Day 1 in all treatment groups and remained elevated until the end of the 
study (Figure 2). Overall SCS differed between strains (p<0.05), and the rise in SCS was less 
evident in the cows challenged with strain S523.  
Discussion 
This study compared the ability of four strains of S. uberis to induce clinical mastitis in healthy 
quarters after intramammary inoculation of two different bacterial concentrations and resulted in the 
identification of one suitable strain for subsequent clinical trials. 
The overall percentage of quarters diagnosed with clinical mastitis was 54% with variability 
observed between the four different strains. The percentage of cases observed was low compared 
with other studies carried out using different strains of S. uberis. Oliver et al. (2003) and Rambeaud 
et al. (2003) reported approximately 80% of quarters developing clinical mastitis following 
challenge using a single S. uberis strain UT888, and 90–100% being reported using other strains 
(Hillerton and Bramley 1989; Pryor et al. 2009).  
The RR for development of mastitis was significant for strain S418 compared with the other strains. 
There were also differences in the SCS measured in composite milk samples following challenge, 
even if only one or two infected quarters per cow were present. Logistic limitations of the study 
meant that quarter milk samples could not be obtained, so analysis of the direct effect of challenge 
with the four strains on SCS was not possible. The other limitation of this study was the modest 
number of cows challenged compared to other studies. 
It has been postulated that survival of different S. uberis strains in the mammary gland might be 
multifactorial and related to individual strain virulence factors and adaptability to the host (Pryor et 














































the prevalence of mastitis differed between the strains despite the strains being exposed to similar in 
vitro and in vivo conditions; i.e. similar inoculation method, cows were from a single farm and 
treatments were balanced for milk yield, and of comparable ages. 
The challenge dose for strain S523 were greater than most of the other strains but this strain resulted 
in the lowest number of clinical cases and the increase in SCS was relatively moderate in 
comparison with the other strains. Conversely, strain 26LB had the lowest viable bacterial counts, 
but produced more clinical cases than strain S523. It is therefore likely that there were strain-related 
virulence mechanisms responsible for these differences, which overwhelmed any possible dose 
effect.  
The peak of clinical mastitis incidence was observed 48–72 hours after challenge. Rambeaud et al. 
(2003) observed a peak in the number of new clinical cases later, at 144 hours after challenge, when 
using a challenge suspension at a dose of 3.3 x 104 cfu for Jersey cows and 5.2 x 104 cfu for 
Holstein cows, slightly lower than the dose used in the present study. In another study, inoculation 
of 7.5 x 103 cfu/ challenge suspension generated the highest number of cases on 7 days after 
challenge (Oliver et al. 2003). It is possible that there is a relationship between the infective dose 
and the time of onset of clinical mastitis, but not necessarily between the infective dose and mastitis 
prevalence. Previous studies have demonstrated mastitis prevalence after challenge was associated 
with a strain’s virulence rather than the infective dose used (Leigh 1999; Oliver et al. 2003; 
Rambeaud et al. 2003). The host immune system is another factor that is likely to contribute to 
differences in development of clinical mastitis following infection (Sordillo and Streicher 2002; 
Moyes et al. 2009).  
It was important to isolate bacteria after culture of the milk samples in order to demonstrate that the 
pathogen inoculated was responsible for the clinical cases observed. Interestingly, only 1/6 cases 
diagnosed following challenge with strain 26LB resulted in isolation of S. uberis after culture. The 
milk culturing technique used in this study used a 10 μL aliquot of milk for culture on the agar 
plates. It is common to find approximately 10% of the samples to be negative at culture when 
inoculating such a small volume of milk (Milne et al. 2005). However, low inoculum volume alone 
does not explain such a low proportion of positive culture results in the case of this strain. Again, 
strain-related factors are likely to have played a role (Tassi et al. 2013). The lack of genetic typing 
data for the strains used in this study was a limitation.  
This paper describes an experimental challenge model of clinical mastitis using four field strains of 














































a safe and cost-effective manner, and could have additional scientific value for the study of the host 
response and further characterisation of the pathogenicity of the organisms.  
The differences observed between the strains in some of the outcomes measured appeared to be 
related to the characteristics of the strains, rather than the number of bacteria inoculated. Challenge 
with strain S418 resulted in the highest prevalence of clinical mastitis whereas strain S523 resulted 
in the lowest prevalence. The proportion of cases of mastitis from which S. uberis could be isolated 
after challenge with strain 26LB was lower than the other strains. Based on its moderate ability to 
produce clinical mastitis in lactating cows and isolation after culture, S. uberis strain SR115 was 
selected for use in further experiments using challenge models. Taken together these results also 
predict a significant variability in the pathogenicity of S. uberis strains under field conditions.   
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Table 1. Results of a challenge study to examine differences between two concentrations of 
four strains of Streptococcus uberis infused into the quarters of lactating dairy cows 
(n=24), showing the dose of bacteria given, the proportion of quarters diagnosed with 
clinical mastitis, the median interval to diagnosis of the first case of mastitis, and the 
proportion of quarters with mastitis from which S. uberis was cultured. 
 
    Clinical mastitis 
Strain Concentration Dose (cfu)  Quarters Mean survival (95%CI) a 
S. uberis 
isolated 
S418 Low 9.84 x 104  6/6   
 High 4.26 x 106  6/6   
 All   12/12  2.42 (2.02–2.81) 12/12 
       
SR115 Low 5.92 x 104  2/6   
 High 2.56 x 106  5/6   
 All   7/12  3.17 (2.62–3.72) 6/7 
       
26LB Low 2.4 x 103  4/6   
 High 1.58 x 105  2/6   
 All   6/12 3.83 (3.31–4.36) 1/6 
       
S523 Low 1.2 x 105  1/6   
 High 2.96 x 106  0/6   
 All   1/12 3 1/1 

















































Figure 1. Cumulative percentage of quarters of lactating dairy cows (n=24) diagnosed with 
clinical mastitis following intramammary inoculation (challenge) with one of four strains of 
Streptococcus uberis on Day 0; strain S418 ( -■- ), strain SR115 ( -▲- ), strain 26LB ( -♦- ) 
and strain S523 ( -●- ). 
 
Figure 2. Mean (± SEM) somatic cell score (log2 somatic cell count/1000) of lactating dairy 
cows (n=24) before and after intramammary inoculation (challenge) with one of four strains 
of Streptococcus uberis on Day 0; strain S418 ( -■- ), strain SR115 ( -▲- ), strain 26LB ( -♦- ) 
and strain S523 ( -●- ). 
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